Soleimani Mohammad, Tabatabaei Seyed Ali, Mirzaei Arash, Esfandiari Amirreza, Soleymanzadeh Mahdi, Sadeghi Reza, Rad Afagh Hassanzadeh
Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Pediatric Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Oman J Ophthalmol. 2023 Feb 21;16(1):69-74. doi: 10.4103/ojo.ojo_180_22. eCollection 2023 Jan-Apr.
Keratoconjunctivitis is one of the most common pathologies worldwide, caused by several infectious and noninfectious factors. This study aimed to determine the effect of povidone-iodine 2% eye drops in treating adenoviral keratoconjunctivitis.
This analytic cross-sectional study was conducted on patients referred to Farabi Eye Hospital Records of patients with adenoviral keratoconjunctivitis, more than 12 years of age, and no allergy to iodine who were treated by povidone-iodine 2% eye drops four times a day were assessed. Data included demographic characteristics, family history of adenoviral keratoconjunctivitis, follicular conjunctivitis, petechial conjunctival hemorrhages, periauricular lymphadenopathy, and the presence of conjunctival pseudomembrane were collected from the records. Discharge decrease, injection decrease, swelling decrease, pseudomembrane formation, periauricular lymphadenopathy, and subepithelial infiltration on the 7day of assessment by physical examination were reported.
Patients with a mean (±standard deviation) age of 33.77 (11.01) years were assessed. At the baseline, 95 (99.0%) follicular conjunctivitis, 94 (97.9%) petechial conjunctival hemorrhages, 29 (30.2%) periauricular lymphadenopathy, and 5 (5.2%) conjunctival pseudomembrane were recorded. On the 7day of treatment, the discharge decreased in 92.7% of patients, and the injection decreased in 90.6%. The swelling decrease was also detected in 79.2% of patients. Subepithelial infiltration was only seen in 21.9% of the study population. Results showed that 2.1% of patients had periauricular lymphadenopathy, and only 13 out of 96 patients (13.5%) had pseudomembrane formation after 7 days.
Based on the safety, availability, and tolerability of povidone-iodine and its promising effects on patients with adenoviral keratoconjunctivitis, further clinical trials assessing the impact of this drug in a longer duration of follow-up can be recommended.
角结膜炎是全球最常见的病症之一，由多种感染性和非感染性因素引起。本研究旨在确定2%聚维酮碘滴眼液治疗腺病毒性角结膜炎的效果。
本分析性横断面研究针对转诊至法拉比眼科医院的患者开展。对年龄超过12岁、对碘不过敏且每天使用4次2%聚维酮碘滴眼液治疗的腺病毒性角结膜炎患者的记录进行评估。从记录中收集的数据包括人口统计学特征、腺病毒性角结膜炎家族史、滤泡性结膜炎、结膜瘀点出血、耳周淋巴结病以及结膜假膜的存在情况。通过体格检查报告在评估第7天时分泌物减少、充血减轻、肿胀减轻、假膜形成、耳周淋巴结病以及上皮下浸润的情况。
评估了平均（±标准差）年龄为33.77（11.01）岁的患者。基线时，记录到95例（99.0%）滤泡性结膜炎、94例（97.9%）结膜瘀点出血、29例（30.2%）耳周淋巴结病以及5例（5.2%）结膜假膜。治疗第7天时，92.7%的患者分泌物减少，90.6%的患者充血减轻。79.2%的患者也出现肿胀减轻。仅21.9%的研究人群出现上皮下浸润。结果显示，2.1%的患者有耳周淋巴结病，96例患者中只有13例（13.5%）在7天后出现假膜形成。
基于聚维酮碘的安全性、可获得性和耐受性及其对腺病毒性角结膜炎患者的良好效果，可推荐进一步开展临床试验，评估该药物在更长随访期内的影响。
